ERBB3 expression

News alerts, weekly reports and conference planners

Entrez ID:

2065

Related biomarkers:

‹

›

ERBB3 expression	Renal Cell Carcinoma	ERBB3 expression	Renal Cell Carcinoma	177Lu-satetraxetan-lilotomab Sensitive: D – Preclinical AACR 2023 - 2 weeks (New D) 177Lu-satetraxetan-lilotomab Sensitive : D AACR 2023 - 2wk	177Lu-satetraxetan-lilotomab Sensitive: D – Preclinical AACR 2023 - 2 weeks 177Lu-satetraxetan-lilotomab Sensitive : D AACR 2023 - 2 weeks - (New D)
ERBB3 expression	Renal Cell Carcinoma	ERBB3 expression	Renal Cell Carcinoma	Ac-225 ErbB3 targeted radiotherapy Sensitive: D – Preclinical AACR 2023 - 2 weeks (New D) Ac-225 ErbB3 targeted radiotherapy Sensitive : D AACR 2023 - 2wk	Ac-225 ErbB3 targeted radiotherapy Sensitive: D – Preclinical AACR 2023 - 2 weeks Ac-225 ErbB3 targeted radiotherapy Sensitive : D AACR 2023 - 2 weeks - (New D)
ERBB3 expression	Prostate Cancer	ERBB3 expression	Prostate Cancer	177Lu-satetraxetan-lilotomab Sensitive: D – Preclinical AACR 2023 - 2 weeks (New D) 177Lu-satetraxetan-lilotomab Sensitive : D AACR 2023 - 2wk	177Lu-satetraxetan-lilotomab Sensitive: D – Preclinical AACR 2023 - 2 weeks 177Lu-satetraxetan-lilotomab Sensitive : D AACR 2023 - 2 weeks - (New D)
ERBB3 expression	Prostate Cancer	ERBB3 expression	Prostate Cancer	Ac-225 ErbB3 targeted radiotherapy Sensitive: D – Preclinical AACR 2023 - 2 weeks (New D) Ac-225 ErbB3 targeted radiotherapy Sensitive : D AACR 2023 - 2wk	Ac-225 ErbB3 targeted radiotherapy Sensitive: D – Preclinical AACR 2023 - 2 weeks Ac-225 ErbB3 targeted radiotherapy Sensitive : D AACR 2023 - 2 weeks - (New D)
ERBB3 expression	Colorectal Cancer	ERBB3 expression	Colorectal Cancer	177Lu-satetraxetan-lilotomab Sensitive: D – Preclinical AACR 2023 - 2 weeks (New D) 177Lu-satetraxetan-lilotomab Sensitive : D AACR 2023 - 2wk	177Lu-satetraxetan-lilotomab Sensitive: D – Preclinical AACR 2023 - 2 weeks 177Lu-satetraxetan-lilotomab Sensitive : D AACR 2023 - 2 weeks - (New D)
ERBB3 expression	Colorectal Cancer	ERBB3 expression	Colorectal Cancer	Ac-225 ErbB3 targeted radiotherapy Sensitive: D – Preclinical AACR 2023 - 2 weeks (New D) Ac-225 ErbB3 targeted radiotherapy Sensitive : D AACR 2023 - 2wk	Ac-225 ErbB3 targeted radiotherapy Sensitive: D – Preclinical AACR 2023 - 2 weeks Ac-225 ErbB3 targeted radiotherapy Sensitive : D AACR 2023 - 2 weeks - (New D)
ERBB3 expression	Ovarian Cancer	ERBB3 expression	Ovarian Cancer	177Lu-satetraxetan-lilotomab Sensitive: D – Preclinical AACR 2023 - 2 weeks (New D) 177Lu-satetraxetan-lilotomab Sensitive : D AACR 2023 - 2wk	177Lu-satetraxetan-lilotomab Sensitive: D – Preclinical AACR 2023 - 2 weeks 177Lu-satetraxetan-lilotomab Sensitive : D AACR 2023 - 2 weeks - (New D)
ERBB3 expression	Ovarian Cancer	ERBB3 expression	Ovarian Cancer	Ac-225 ErbB3 targeted radiotherapy Sensitive: D – Preclinical AACR 2023 - 2 weeks (New D) Ac-225 ErbB3 targeted radiotherapy Sensitive : D AACR 2023 - 2wk	Ac-225 ErbB3 targeted radiotherapy Sensitive: D – Preclinical AACR 2023 - 2 weeks Ac-225 ErbB3 targeted radiotherapy Sensitive : D AACR 2023 - 2 weeks - (New D)
ERBB3 expression	Lung Cancer	ERBB3 expression	Lung Cancer	DB-1310 Sensitive: D – Preclinical AACR 2023 - 2 weeks (New D) DB-1310 Sensitive : D AACR 2023 - 2wk	DB-1310 Sensitive: D – Preclinical AACR 2023 - 2 weeks DB-1310 Sensitive : D AACR 2023 - 2 weeks - (New D)
ERBB3 expression	Breast Cancer	ERBB3 expression	Breast Cancer	DB-1310 Sensitive: D – Preclinical AACR 2023 - 2 weeks (New D) DB-1310 Sensitive : D AACR 2023 - 2wk	DB-1310 Sensitive: D – Preclinical AACR 2023 - 2 weeks DB-1310 Sensitive : D AACR 2023 - 2 weeks - (New D)
ERBB3 expression	HER2 Positive Breast Cancer	ERBB3 expression	HER2 Positive Breast Cancer	ado-trastuzumab emtansine Sensitive: B - Late Trials ado-trastuzumab emtansine Sensitive : B	ado-trastuzumab emtansine Sensitive: B - Late Trials ado-trastuzumab emtansine Sensitive : B
ERBB3 expression	Colorectal Cancer	ERBB3 expression	Colorectal Cancer	U3-1402 Sensitive: C2 – Inclusion Criteria U3-1402 Sensitive : C2	U3-1402 Sensitive: C2 – Inclusion Criteria U3-1402 Sensitive : C2
ERBB3 expression	Breast Cancer	ERBB3 expression	Breast Cancer	U3-1402 Sensitive: C2 – Inclusion Criteria U3-1402 Sensitive : C2	U3-1402 Sensitive: C2 – Inclusion Criteria U3-1402 Sensitive : C2
ERBB3 expression	Colorectal Cancer	ERBB3 expression	Colorectal Cancer	cetuximab Sensitive: C3 – Early Trials cetuximab Sensitive : C3	cetuximab Sensitive: C3 – Early Trials cetuximab Sensitive : C3
ERBB3 expression	Endometrial Cancer	ERBB3 expression	Endometrial Cancer	lapatinib Resistant: D – Preclinical lapatinib Resistant : D	lapatinib Resistant: D – Preclinical lapatinib Resistant : D
ERBB3 expression	Bladder Cancer	ERBB3 expression	Bladder Cancer	lapatinib Resistant: D – Preclinical lapatinib Resistant : D	lapatinib Resistant: D – Preclinical lapatinib Resistant : D
ERBB3 expression	Melanoma	ERBB3 expression	Melanoma	U3-1402 Sensitive: D – Preclinical U3-1402 Sensitive : D	U3-1402 Sensitive: D – Preclinical U3-1402 Sensitive : D
ERBB3 expression	Pancreatic Cancer	ERBB3 expression	Pancreatic Cancer	afatinib Sensitive: D – Preclinical afatinib Sensitive : D	afatinib Sensitive: D – Preclinical afatinib Sensitive : D
ERBB3 expression	Pancreatic Cancer	ERBB3 expression	Pancreatic Cancer	pertuzumab Sensitive: D – Preclinical pertuzumab Sensitive : D	pertuzumab Sensitive: D – Preclinical pertuzumab Sensitive : D
ERBB3 expression	Estrogen Receptor Positive Breast Cancer	ERBB3 expression	Estrogen Receptor Positive Breast Cancer	U3-1402 Sensitive: D – Preclinical U3-1402 Sensitive : D	U3-1402 Sensitive: D – Preclinical U3-1402 Sensitive : D

ERBB3 expression

Associations